This study looks at the best dose and side effects of a cancer drug called melphalan for patients with multiple myeloma, a type of blood cancer. Doctors use melphalan and other chemotherapy drugs to stop cancer cells from growing or spreading. In this trial, the dose is personalized by checking how much melphalan is in each person's blood, which is called *pharmacokinetic analysis*. This helps doctors understand how to give the right amount of the drug to each patient.
Key Points:
- Duration and Visits: The treatment involves hospital visits for doses and follow-ups for 90 days.
- Risks: Possible side effects could include damage to DNA and other toxicities. Discuss with your doctor if it's safe for you.
- Eligibility: Patients must have certain blood counts and organ functions. Women must not be pregnant and agree to use birth control.
Patients will receive melphalan through an IV (intravenous) line and then undergo a stem cell transplant. After treatment, patients will be checked at specific intervals (7, 14, 30, 60, and 90 days) to ensure their safety and the effectiveness of the treatment.
How understandable was the trial content above?
Hard to understand
Easy to understand